# Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

> **NCT00063089** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Staphylococcal Infections

## Interventions

- **DRUG:** S. aureus Immune Globulin Intravenous (Human) 5%

## Key facts

- **NCT ID:** NCT00063089
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063089, "Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00063089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*